Recent studies suggested that Rb loss and/or p16 overexpression could be associated with prolonged OS under EP chemotherapy in pulmonary LCNEC (SCLC-like subtype) [10,27] and an increased response to EP therapy in pancreatic G3 NEN [28,29]. Here, RB1 is linked to small cell lung carcinoma.